// LIVE.FEED

Frontier signal stream

01 Sep 2026 00:00
⚖️ Regulatory & Approvals

Tennessee issues licence for fusion plant

The Tennessee Department of Environment and Conservation issued the state's first fusion-specific byproduct material license to Type One Energy for its commercial fusion project, making Tennessee the first US state to license a commercial fusion machine under a new regulatory framework.

World Nuclear NewsUNLISTED SOURCEC
16 Jun 2026 00:00
⚖️ Regulatory & Approvals★ BIG

Helion Energy becomes first US fusion company to secure all regulatory licenses for a fusion power plant

Helion received the licenses from Washington State's Department of Health needed to build and operate its 50MW fusion plant in Malaga, WA — the first US (and per the company, world-first) fusion firm to clear the full regulatory path for a power plant. It clears a key gate toward construction of a plant slated to supply Microsoft.

ReutersPRESSA
28 Apr 2026 00:00
⚖️ Regulatory & Approvals

Commonwealth Fusion Systems becomes first fusion company to apply for grid interconnection — files to connect first ARC plant (~400MWe) to PJM

CFS submitted an interconnection request to PJM Interconnection (the largest U.S. wholesale electricity market) to connect its first ARC fusion power plant in Chesterfield County, Virginia, targeting power delivery in the early 2030s. It is the first fusion company ever to enter a grid-interconnection queue — a concrete, regulated step from R&D toward commercial generation.

Commonwealth Fusion Systems (company press release)PRESSA
26 Mar 2026 00:00
⚖️ Regulatory & Approvals

Ilumira (n.c.a. lutetium-177) receives EU-wide marketing authorisation

The European Commission granted Ilumira, SHINE's non-carrier-added lutetium-177 chloride, a centralised marketing authorisation valid throughout the European Union on 26 March 2026, per the EMA's own EPAR record (reference EMA/48983/2026, first published 1 April 2026). Ilumira is a radiolabelling agent — never given directly to a patient — used to label other medicines that carry Lu-177 to tumour sites, with presented data covering neuroendocrine tumours and prostate cancer. The clearance is the regulatory prerequisite for selling Lu-177 into the EU and opens one of the world's largest radioligand-therapy markets to a US-based supplier. DATE PRECISION: SHINE did not announce this until 29 May 2026, 64 days after the authorisation date. This record is dated to the regulator's decision, not the company's announcement.

European Medicines Agency (EPAR)REGULATORA